KaplanJKrieffD. Quinolones for the treatment and prophylaxis of tuberculosis. Ann Pharmacother1996; 30: 1020–2.
2.
PeloquinCABerningSE. Infections caused by Mycobacterium tuberculosis. Ann Pharmacother1994; 28: 72–84.
3.
ReichmanLB. The U-shaped curve of concern. Am Rev Respir Dis1991; 144: 741–2.
4.
MorNVanderkolkJHeifetsL. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob Agents Chemother1994; 38: 1161–4.
5.
KlopmanGWangSJacobsMRBajaksouzianSEdmondsKEllnerJJ. Anti-Mycobacterium avium activity of quinolones: in vitro activities. Antimicrob Agents Chemother1993; 37: 1799–806.
BerningSEMadsenLIsemanMDPeloquinCA. Long-term safety of ofloxacin and ciprofloxacin in the treatment of mycobacterial infections. Am J Respir Crit Care Med1995; 151: 2006–9.
8.
PeloquinCABerningSEMadsenLIsemanMD. Ofloxacin and ciprofloxacin in the treatment of mycobacterial infections: development of resistance and drug interactions. J Infect Dis Pharmacother1995; 1: 45–65.
9.
HornDLHewlettDAlfallaCPetersonS. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis (letter). N Engl J Med1994; 330: 1241.
10.
YewWWWongCFLeeJChauCH. Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin. Clin Infect Dis1993; 17: 288–9.
11.
Package insert. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, 1995.
12.
PeloquinCA. Pharmacology of the antimycobacterial drugs. Med Clin North Am1993; 77: 1253–62.
